Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden

被引：0
|
作者：
Johan Lundberg
Martin Höglund
Magnus Björkholm
Örjan Åkerborg
机构：
[1] MSD Sweden (AB),Outcomes Research
[2] University Hospital,Division of Hematology, Department of Medical Science
[3] Karolinska University Hospital Solna,Department of Medicine
[4] Optum Insight,undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
Acute Myeloid Leukemia; Fluconazole; Itraconazole; Invasive Aspergillosis; Acute Myeloid Leukemia Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：483 / 489
页数：6
相关论文
共 50 条
  • [1] Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden
    Lundberg, Johan
    Hoglund, Martin
    Bjorkholm, Magnus
    Akerborg, Orjan
    CLINICAL DRUG INVESTIGATION, 2014, 34 (07) : 483 - 489
  • [2] COST-EFFECTIVENESS OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN SINGAPORE
    Fust, K.
    Weinstein, M. C.
    Gomez-Rey, G.
    Xie, Y.
    Hsu, T. Y.
    Pawar, V
    Hsu, L. Y.
    Tan, B. H.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2013, 16 (03) : A138 - A139
  • [3] Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
    Grau, Santiago
    de la Camara, Rafael
    Sabater, Francisco J.
    Jarque, Isidro
    Carreras, Enric
    Casado, Miguel A.
    Sanz, Miguel A.
    BMC INFECTIOUS DISEASES, 2012, 12
  • [4] COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO
    Rely, K.
    Pierre, K. A.
    Salinas, E. G.
    VALUE IN HEALTH, 2009, 12 (03) : A50 - A50
  • [5] COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO
    Rely, K.
    Pierre, K. A.
    Salinas, E. G.
    VALUE IN HEALTH, 2009, 12 (07) : A490 - A491
  • [6] Incidence and mortality of invasive fungal infections in high-risk patients receiving posaconazole versus fluconazole or itraconazole prophylaxis
    Langston, A.
    Lipton, J. H.
    Comely, O. A.
    Ullnumn, A. J.
    Patino, H.
    Hardalo, C.
    Winston, D. J.
    Chandnisekar, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 33 - 33
  • [7] COST-EFFECTIVENESS OF POSACONAZOLE COMPARED TO FLUCONAZOLE/ITRACONAZOLE FOR THE PREVENTION OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS
    Athanasakis, K.
    Petrakis, I
    Kyriopoulos, J.
    VALUE IN HEALTH, 2012, 15 (07) : A393 - A393
  • [8] COST-EFFECTIVENESS OF POSACONAZOLE VERSUS FLUCONAZOLE OR ITRACONAZOLE IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG NEUTROPENIC PATIENTS IN THE UNITED STATES
    Xie, Y.
    Pawar, V
    VALUE IN HEALTH, 2013, 16 (03) : A91 - A91
  • [9] Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States
    O'Sullivan, Amy K.
    Pandya, Ankur
    Papadopoulos, George
    Thompson, David
    Langston, Amelia
    Perfect, John
    Weinstein, Milton C.
    VALUE IN HEALTH, 2009, 12 (05) : 666 - 673
  • [10] Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
    Santiago Grau
    Rafael de la Cámara
    Francisco J Sabater
    Isidro Jarque
    Enric Carreras
    Miguel A Casado
    Miguel A Sanz
    BMC Infectious Diseases, 12
12345